TCR diversity – a universal cancer immunotherapy biomarker?
Sipuleucel-T was approved as a treatment for men with advanced metastatic, castration-resistant prostate cancer on the basis of improved survival in randomized clinical trials. A major challenge for this therapy, as well as other newer cancer immunotherapy agents, has been to identify markers that c...
| Published in: | Journal for ImmunoTherapy of Cancer |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2016-11-01
|
| Online Access: | https://jitc.bmj.com/content/4/1/69.full |